Recent Imbruvica Approval Indicates CLL is Moving Towards Cure

Imbruvica is now approved to treat CLL (Chronic Lymphoid Leukemia) patients regardless of their history of treatment (treatment-naïve and previously-treated patients). Furthermore, Imbruvica is approved to treat CLL patients at high-risk with del 17p, a genetic aberration that occurs when part of chromosome 17, the location of the tumor suppressor gene p53, has been lost or removed.


CLL is a slow-growing #bloodcancer, which often arises from B cells, a type of white blood cells (lymphocyte) which originates in the bone marrow, CLL is predominantly a disease of the elderly, with a median age of 71 years at diagnosis.


#IMBRUVICA works by blocking a specific protein called Bruton’s tyrosine kinase (BTK). The BTK protein sends important signals that tell B cells to mature and produce antibodies and is needed by specific cancer cells to multiply and spread, IMBRUVICA targets and blocks BTK, inhibiting the survival of cancer cells and spread.